Navigation Links
Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy
Date:3/20/2009

herapy related weight loss."

"These results are of special interest in light of ensuring an even more effective supportive care to patients undergoing high emetogenic chemotherapy. From this point of view, such an outcome is consistent with Helsinn's commitment in this particular setting," stated Prof. Mauro Bianchi, Medical Development Director at Helsinn.

About Chemotherapy-induced nausea and vomiting (CINV)

Chemotherapy-induced nausea and vomiting is among the most dreaded side effects following therapy in patients with cancer. Despite prophylaxis, on the day of chemotherapy, up to 30-45 percent of patients experience nausea or vomiting or require rescue therapy following administration of certain types of emetogenic chemotherapy. The 5-HT3 receptor plays a pivotal role in the process of emesis, and agents that antagonise these receptor subtypes are the basis for control of this effect. Following the development of the first generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in recent years new compounds have been made available for preventing CINV, including palonosetron.

About Palonosetron (Aloxi(R), Onicit(R), Paloxi(R))

Palonosetron (palonosetron hydrochloride) is a selective 5-HT3 receptor antagonist, developed for the prevention of CINV in patients with cancer, with a long half-life of 40 hours and at least 30 times higher receptor binding affinity than currently available compounds. Palonosetron is a second generation 5-HT3 receptor antagonist, and demonstrates, in clinical trials and clinical practice, a unique long-lasting action in the prevention of CINV. Since its availability in USA in September 2003, and since then in more than 40 countries world-wide, there have been over 10 million administrations of palonosetron. The product has shown to be effective in preventing both acute and delayed CINV in patie
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
2. Imagenetix Reports Results of Offer to Extend Warrants
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
9. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
10. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... plc (NYSE: ACT ) today confirmed that a ... Second Circuit has issued a ruling upholding a December ... distribution of NAMENDA ® (memantine HCl) immediate-release tablets. ... "While we are disappointed by the Court,s decision ... strong efforts to convey the significant benefits of NAMENDA ...
(Date:5/22/2015)... NJ (PRWEB) May 22, 2015 ... new white paper that explores the potential of big ... The white paper was developed to help life sciences ... can leverage data to gain critical business insights. , ... large amounts of data driven by patient profiling, compliance ...
(Date:5/21/2015)... St. Louis, MO (PRWEB) May 21, 2015 ... that assesses the safety and efficacy of pharmaceutical products ... Access Drive Maryland Heights, MO 63043, a 50,000 sq. ... their current location, to enable strategic growth. Facility renovations ... offices to the new space will occur in September. ...
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... March 27, 2012 Vermillion, Inc. (NASDAQ: ... and operational results for the fourth quarter and full ... Full Year 2011 Operational Highlights In ... diagnostic designed to help differentiate benign from malignant ovarian ...
... March 26, 2012 The L,ORÉAL-UNESCO For Women in ... a week of scientific meetings and debates. , ... International Fellows will be presenting their research at the Pasteur Institute ... at the Institute where the International Fellows can be met individually ...
... massive particles has intrigued physicists for more than 80 years, ... behaviour in conflict with our everyday ideas of what ... now succeeded in shooting a movie which shows the build-up ... is so large (up to 0.1 mm) that you can ...
Cached Biology Technology:Vermillion Reports Fourth Quarter and Full Year 2011 Results 2Vermillion Reports Fourth Quarter and Full Year 2011 Results 3Vermillion Reports Fourth Quarter and Full Year 2011 Results 4Vermillion Reports Fourth Quarter and Full Year 2011 Results 5Vermillion Reports Fourth Quarter and Full Year 2011 Results 6Vermillion Reports Fourth Quarter and Full Year 2011 Results 7Vermillion Reports Fourth Quarter and Full Year 2011 Results 8The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... believes his latest work moves scientists closer to a cure ... genetic diseases. , The Journal of Biological Chemistry ... the School of Medicine,s Department of Medical Pharmacology and Physiology ... recognized as the "paper of the week" for the journal, ...
... In an expansion of its ongoing effort to promote ... York Stem Cell Foundation (NYSCF) today named the first ... Investigators will receive up to $1.5 million over the ... other scientists and foster innovative high-risk/high reward research to ...
... Calif., Oct. 12 Stayhealthy, Inc. an innovative, ... fitness measurement, announced that it will join Hooper ... wellness, prevention and chronic care management October 13-15 ... healthcare decision makers. Earlier this year, Stayhealthy announced ...
Cached Biology News:1 step closer to a drug treatment for cystic fibrosis, MU professor says 2NYSCF announces 2010 NYSCF Investigators 2NYSCF announces 2010 NYSCF Investigators 3NYSCF announces 2010 NYSCF Investigators 4NYSCF announces 2010 NYSCF Investigators 5Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 2Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 3Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 4
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
...
... The epitope specific for Nabeta2 ... other known proteins.,SPECIES REACTIVITIES: ... on human because the immunogen ... residues). Reactivity with other species ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: